Successful treatment of pustulotic arthro-osteitis with apremilast: a case report with follow-up MRI

Takama, Hiroyuki; Ando, Yoko; Yanagishita, Takeshi; Ohshima, Yuichiro; Akiyama, Masashi; Watanabe, Daisuke

doi:10.1684/ejd.2019.3660

Cited by 4 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its effectiveness was also demonstrated in patients with pustulosis arthro-osteitis, an entity with overlapping features with SAPHO syndrome 72 …”

Section: Pharmacological Optionsmentioning

confidence: 99%

“…71 Its effectiveness was also demonstrated in patients with pustulosis arthro-osteitis, an entity with overlapping features with SAPHO syndrome. 72 Adamo et al 51 reported a case of SAPHO patient refractory to UST and SEC treated with apremilast using the psoriasis therapeutic regimen. This treatment was effective on both skin and joint symptoms.…”

Section: Phosphodiesterase 4 Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological Management of Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome Syndrome

Slouma

Bettaieb²,

Rahmouni³

et al. 2021

J Clin Rheumatol

View full text Add to dashboard Cite

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic disease with marked clinical and radiological heterogeneity. It is characterized by a combination of dermatological and osteoarticular manifestations. The treatment of SAPHO syndrome is not yet codified. It includes several therapeutic options such as anti-inflammatory drugs, bisphosphonates, antibiotics, conventional disease-modifying antirheumatic drugs, and biological treatment.This article aims to provide an updated review of the different pharmacological options for SAPHO syndrome. We also propose a therapeutic algorithm for the management of this disease.

show abstract

“…Its effectiveness was also demonstrated in patients with pustulosis arthro-osteitis, an entity with overlapping features with SAPHO syndrome 72 …”

Section: Pharmacological Optionsmentioning

confidence: 99%

Section: Phosphodiesterase 4 Inhibitorsmentioning

confidence: 99%

Pharmacological Management of Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome Syndrome

Slouma

Bettaieb²,

Rahmouni³

et al. 2021

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…It commonly affects the clavicle, sternum, and sternoclavicular and sternocostal joints. 1 PAO is treated by removal of focal infection, 2,3 non-steroidal anti-inflammatory drugs (NSAIDs), 4 cyclosporin, 5,6 apremilast, 7,8 methotrexate, sulfasalazine and/or biologics. 9,10 In Japan, guselkumab (GUS), an anti-interleukin-23p19 antibody, was approved for PPP in 2018.…”

Section: Introductionmentioning

confidence: 99%

Guselkumab improves joint pain in patients with pustulotic arthro‐osteitis: A retrospective pilot study

Ikumi

Fujita

Terada

2020

The Journal of Dermatology

View full text Add to dashboard Cite

Pustulotic arthro‐osteitis (PAO) is an osteoarticular complication of palmoplantar pustulosis (PPP). Although guselkumab, an anti‐interleukin‐23p19 antibody, has been shown to be effective for PPP, its efficacy for PAO is still not well understood. We conducted a retrospective observational study to evaluate the effectiveness of 28‐week guselkumab treatment for five PAO patients in daily clinical practice. Four patients had sternoclavicular arthritis, and one had only sacroiliitis. Guselkumab improved pain visual assessment scale scores in all five patients by 54.2% (11.1–87.5%) on average at week 28 compared with baseline, and discontinuation or dose reduction of analgesics was possible in four of them. Three patients showed clinically significant improvement in Bath Ankylosing Spondylitis Disease Activity Index of 2 or more. On the other hand, beneficial change in Ankylosing Spondylitis Disease Activity Score of 1.1 or more was observed in only one patient. Bone scintigraphy demonstrated decreased uptake in sternoclavicular joints after guselkumab treatment in all four patients with sternoclavicular arthritis. Improvement of Palmoplantar Pustulosis Area and Severity Index was also confirmed. Guselkumab can be a treatment option for intractable PAO.

show abstract

“…Apremilast blocks phosphodiesterase-4, which regulates immune and inflammatory process through modification of the levels of intracellular cyclic adenosine monophosphate, protein kinase A, and various inflammatory cytokine production. To date, only a few cases have been reported on apremilast therapy for PAO or SAPHO syndrome (Adamo et al, 2018;Eto, Nakao, & Furue, 2019;Takama et al, 2019).…”

mentioning

confidence: 99%

Effects of apremilast on pustulotic arthro‐osteitis in a real‐world setting: Report of five cases

Kikuchi

Yamamoto

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Successful treatment of pustulotic arthro-osteitis with apremilast: a case report with follow-up MRI

Cited by 4 publications

References 6 publications

Pharmacological Management of Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome Syndrome

Pharmacological Management of Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome Syndrome

Guselkumab improves joint pain in patients with pustulotic arthro‐osteitis: A retrospective pilot study

Effects of apremilast on pustulotic arthro‐osteitis in a real‐world setting: Report of five cases

Contact Info

Product

Resources

About